Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

obex medical ltd - ioversol 74% (provides 35% (350mg/ml) organically bound iodine) - solution for injection - 74 % - active: ioversol 74% (provides 35% (350mg/ml) organically bound iodine) excipient: sodium calcium edetate trometamol

Kanada - enska - Health Canada

liebel-flarsheim company llc - ioversol - solution - 74% - ioversol 74% - roentgenography

Bandaríkin - enska - NLM (National Library of Medicine)

liebel-flarsheim company llc - ioversol (unii: n3rib7x24k) (ioversol - unii:n3rib7x24k) - ioversol 741 mg in 1 ml - optiray is indicated for: in adults - optiray 300: cerebral arteriography and peripheral arteriography. - optiray 320: cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography. - optiray 350: peripheral arteriography coronary arteriography, and left ventriculography. in pediatric patients - optiray 320 and optiray 350: angiocardiography. in adults - optiray 300: ct imaging of the head and body, venography, and intravenous excretory urography. - optiray 320: ct imaging of the head and body, venography, and intravenous excretory urography. - optiray 350: ct imaging of the head and body, venography, intravenous excretory urography, and intravenous digital subtraction angiography (iv-dsa). - in pediatric patients optiray 320: ct imaging of the head and body, and intravenous excretory urography. symptomatic hyperthyroidism risk summary postmarketing data with optiray use in pregnant women are insufficient to de

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

obex medical ltd - ioversol 74% (provides 35% (350mg/ml) organically bound iodine.) - solution for injection - 74 % - active: ioversol 74% (provides 35% (350mg/ml) organically bound iodine.) excipient: sodium calcium edetate trometamol

Sádi-Arabía - enska - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

liebel flarsheim company llc, united states - ioversol - injection - 350 mg/ml

Bandaríkin - enska - NLM (National Library of Medicine)

liebel-flarsheim company llc - ioversol (unii: n3rib7x24k) (ioversol - unii:n3rib7x24k) - optiray is indicated for: in adults - optiray 300: cerebral arteriography, and peripheral arteriography. - optiray 320: cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography. - optiray 350: peripheral arteriography, coronary arteriography, and left ventriculography. in pediatric patients - optiray 320 and optiray 350: angiocardiography. in adults - optiray 300: ct imaging of the head and body, venography, and intravenous excretory urography. - optiray 320: ct imaging of the head and body, venography, and intravenous excretory urography. - optiray 350: ct imaging of the head and body, venography, intravenous excretory urography, and intravenous digital subtraction angiography (iv-dsa). in pediatric patients - optiray 320: ct imaging of the head and body, and intravenous excretory urography. symptomatic hyperthyroidism. risk summary postmarketing data with optiray use in pregnant women are insufficient

Bandaríkin - enska - NLM (National Library of Medicine)

liebel-flarsheim company llc - ioversol (unii: n3rib7x24k) (ioversol - unii:n3rib7x24k) - optiray is indicated for: in adults - optiray 300: cerebral arteriography, and peripheral arteriography. - optiray 320: cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography. - optiray 350: peripheral arteriography, coronary arteriography, and left ventriculography. in pediatric patients - optiray 320 and optiray 350: angiocardiography. in adults - optiray 300: ct imaging of the head and body, venography, and intravenous excretory urography. - optiray 320: ct imaging of the head and body, venography, and intravenous excretory urography. - optiray 350: ct imaging of the head and body, venography, intravenous excretory urography, and intravenous digital subtraction angiography (iv-dsa). in pediatric patients - optiray 320: ct imaging of the head and body, and intravenous excretory urography. symptomatic hyperthyroidism. risk summary postmarketing data with optiray use in pregnant women are insufficien

Kanada - enska - Health Canada

liebel-flarsheim company llc - ioversol - solution - 74% - ioversol 74% - roentgenography

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

guerbet laboratories ltd - ioversol - solution for infusion - 350mg/1ml

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - ioversol - solution for injection - 350mg/1ml